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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYSpinalmuscular atrophy with respiratory distress type 1 (SMARD1) is a motor neuron disease caused bymutations in the IGHMBP2 gene,
without a cure. Here, we demonstrate that neural stem cells (NSCs) from human-induced pluripotent stem cells (iPSCs) have therapeutic
potential in the context of SMARD1. We show that upon transplantation NSCs can appropriately engraft and differentiate in the spinal
cord of SMARD1 animals, ameliorating their phenotype, by protecting their endogenousmotor neurons. To evaluate the effect of NSCs in
the context of human disease, we generated human SMARD1-iPSCs motor neurons that had a significantly reduced survival and axon
length. Notably, the coculture with NSCs ameliorate these disease features, an effect attributable to the production of neurotrophic fac-
tors and their dual inhibition of GSK-3 and HGK kinases. Our data support the role of iPSC as SMARD1 disease model and their trans-
lational potential for therapies in motor neuron disorders.INTRODUCTION
Spinal muscular atrophy with respiratory distress type 1
(SMARD1, OMIM 604320), also identified as distal spinal
muscular atrophy type 1 (DSMA1), is an autosomal
recessive motor neuron disorder and the second most
frequent form of spinal muscular atrophy after spinal
muscular atrophy (SMA) 5q. SMARD1 is characterized
by a sudden onset of respiratory distress, usually within
the first year of life, with initially distal and later general-
ized muscle weakness (Eckart et al., 2012). SMARD1
results from mutations in the gene encoding the immu-
noglobulin microbinding protein 2 (IGHMBP2), which
encodes an ATPase/helicase that belongs to the SF1 super-
family (Grohmann et al., 2001; Guenther et al., 2009;
Jankowsky et al., 2011). A splice-site mutation in murine
Ighmbp2 causes a neuromuscular disorder similar to the
human disease in the nmd mouse, representing the ani-
mal model of SMARD1 (Cox et al., 1998). How these
molecular abnormalities lead to motor neuron degenera-
tion and the disease phenotype in rodents and humans
is unknown.
No effective therapies are available for motor neuron
diseases, including SMARD1. Neural stem cell (NSC) trans-
plantation represents a possible therapeutic strategy for
ameliorating the neurological phenotype by multiple
mechanisms, including neuroprotection and cell replace-
ment of different CNS cells (Donnelly et al., 2012).Stem CThese positive effects of stem cell transplantation (neural
and nonneural cells) have been demonstrated in earlier
studies by us and other groups (Corti et al., 2006, 2008,
2009, 2010, 2012; Donnelly et al., 2012). As our work has
shown, NSC and neuronal precursor transplantation in
animal models improves the phenotype of motor neuron
diseases, including SMA, SMARD1, and amyotrophic
lateral sclerosis (ALS) (Corti et al., 2006, 2008, 2009,
2010, 2012). In fact, we described that primary murine
NSC transplantation can improve the disease phenotype
in a SMARD1 mouse model (Corti et al., 2006). Further-
more, a phase I safety trial of direct intraspinal transplanta-
tion of NSCs into patients with ALS is in progress, approved
by the US Food and Drug Administration (Boulis et al.,
2011). Recently, Teng et al. has shown the effectiveness of
transplanted NSCs in slowing disease and prolonging
survival in ALS mice, rescuing the phenotype completely
in 25% of cases (survival increased to more than a year
compared to 4 months in untreated animals) (Teng et al.,
2012), but 40% of transplanted animals still show only a
mild survival improvement. These data represent an un-
precedented success in this ALS model because pharmaco-
logical/molecular treatments have up to now not produced
such remarkably successful therapeutic outcomes. One
caveat is represented by the observed variability that might
have to do with some variation in the neuroprotective fea-
tures of transplanted cells and the fact that our understand-
ing of the variables that are critical to therapeutic successell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 297
Figure 1. Differentiation of iPSCs into NSCs and Characterization of Their Phenotypic Properties
(A) Scheme for the differentiation of NSCs from iPSCs. The iPSCs were initially undifferentiated and expressed OCT4. After detaching from
the plate, the iPSCs formed aggregates that were maintained for 7 days in neural medium. The differentiated cells acquired the features of
neuroepithelial (NE) rosettes. The primitive NE cells were positive for PAX6 and nestin. Culturing these cells with RA and SHH generated
OLIG2-expressing motor neurons, which were further phenotypically matured in the presence of neurotrophic factors and reduced con-
centrations of SHH and RA.
(B) iPSC-derived NSCs grown at clonal density in NEP medium generated epithelial-like clones positive for NSC markers such as SOX1, SOX2,
and nestin (red). Scale bar, 100 mm.
(C) After in vitro differentiation, NSCs generated the three neuroectodermal lineages, including TUJ1-positive neurons (green), GFAP-
positive astrocytes (green), and oligodendrocytes expressing O4 (green), as quantified in (D) (right panel).
(D) Quantification of cells positive for NSC-specific markers (D, left panel). Nuclei were counterstained with DAPI (blue signal). n = 5
independent experiments in triplicate. Scale bar, TUJ1 and GFAP, 100 mm; O4, 50 mm.
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that the source of human NSCs, primary CNS tissue (fetal
brain), is limited.
The reprogramming of adult somatic cells into induced
pluripotent stem cells (iPSCs) can provide an unlimited
source of NSCs for therapeutic use (Ito et al., 2012).
Recently, we described that transplantation of a specific
NSC population delayed disease progression and extended
the life span of ALS mice (Nizzardo et al., 2013).
In the present study, we investigated the therapeutic
potential of transplanting human iPSC-derived NSCs into
the spinal cord of nmdmice, which demonstrated that the
engraftment capacity of these cells is associated with an
amelioration of the SMARD1 disease phenotype. NSCs are
especially remarkable because they can promote cell sur-
vival and axonal growth of murine and human SMARD1
motor neurons, which is attributable to the fact that NSCs
inhibit both GSK-3 andHGK kinases. This capacity empha-
sizes that iPSC-derivedNSC-mediated therapies hold prom-
ising translational potential in motor neuron disorders.298 Stem Cell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The AutRESULTS
Generation and Characterization of Neural Stem/
Precursor Cells from iPSCs
We generated and fully characterized iPSC lines using a
nonviral, nonintegrating method (Figure S1 available
online). We applied a multistage differentiation protocol
previously developed to promote the conversion of human
iPSCs into NSCs (Figure 1A) (Corti et al., 2012). These
culture conditions resulted in the emergence of rosette con-
formations typical of neuroepithelial cells. After 7 days,
53.4% ± 6.8% of neural cells expressed Sox1. These cells
were then isolated and expanded in media containing
epidermal growth factor and fibroblast growth factor
(FGF)-2 in adherent conditions. The cells homogeneously
expressed NSC marker proteins such as SOX1, SOX2, and
nestin (89.3% ± 5.7%) (Figures 1B and 1D) were self-renew-
ing and multipotent and could differentiate into the three
major neuroectodermal lineages (Figure 1C). Under differ-
entiation conditions, 53.3% ± 13.8% of the cells generatedhors
Figure 2. iPSC-Derived NSCs Engraft into
the Spinal Cords of nmd Mice after Trans-
plantation
(A) After transplantation, the presence of
donor GFP+ cells was confirmed in the spinal
cord of treated animals. Scale bar, 150 mm.
(B) GFP+ cells were detected in the anterior
horns. Scale bar, 75 mm.
(C) Quantification of the phenotype
acquired by the donor cells revealed the
presence of some undifferentiated cells
(nestin), whereas the rest differentiated
into neuronal (MAP2) and glial cells (GFAP),
with only a minor proportion as oligoden-
drocytes (O4). The error bars indicate the SD
(n = 24 mice per group).
(D–F) Representative images of cells
acquiring a neuronal phenotype positive for
TUJ1 (D, red), MAP2 (E, red), and NEUN (F,
red), as well as for GFP. Scale bars, (D),
75 mm; (E) and (F), 100 mm.
(G) Some cells expressed CHAT (red), sug-
gesting a differentiation of cholinergic
neurons. Scale bar, 100 mm.
(H and I) Donor cells also differentiated
into astrocytes positive for GFAP (H, red) or
maintained an undifferentiated phenotype
expressing nestin (I, red). Nuclei were
counterstained with DAPI (blue signal).
Scale bars, (H) 100 mm; (I) 75 mm.
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iPSC-Derived Neural Stem Cells for SMARD1TUJ1-positive neurons (Figure 1C) with extended neuronal
processes. We then tested whether these NSCs could give
rise to clinically relevant neuronal subtypes such as spinal
cord motor neurons. Following the protocols developed
for human pluripotent stem cells (Hu and Zhang, 2009;
Corti et al., 2012), we exposed the NSCs to sonic hedgehog
(SHH) and retinoic acid (RA) in the presence of neurotro-
phins (Figure 1A). Quantification revealed that the number
of choline acetyltransferase (CHAT)-positive neurons was
37.8% ± 6.9%. In addition to neuronal antigens (MAP2),
these cells also expressed other specific motor neuronal
markers (ISLET-1, HB9) (Figure S2).
Transplanted iPSC-Derived NSCs Engraft into the
SMARD1 Spinal Cord and Differentiate into the Three
Major Neuroectodermal Lineages
To investigate the therapeutic potential of wild-type (WT)
iPSC-derived NSCs, we injected green fluorescent protein
(GFP)-labeled NSCs (10,000 cells 3 two horns at the cervi-
cal and lumbar levels) into SMARD1 mice at 1 day of ageStem C(postnatal day 1) according to a previously described
transplantation protocol. Control mice received only
vehicle or fibroblasts cells. Dye injection, used as a control,
showed the distribution of the injected solution in the spi-
nal cord and the absence of any damage (Figure S3). The
transplanted mice were analyzed at the end stage of the
disease. Transplanted cells were detected in the graymatter
of the treated spinal cord (Figures 2A and 2B). Unbiased
stereological quantification with optical dissectors and
random sampling of GFP-engrafted cells demonstrated
that an average of 8,795 ± 526 donor cells were present
(Table 1).
To analyze the phenotype of engrafted cells, we per-
formed confocal immunohistochemical analysis of neuro-
ectodermal antigens. The human donor cells displayed
various complex neuronal and glial morphologies express-
ing the neuronal marker proteins b-III-tubulin (Figure 2D)
and NEUN (Figure 2F), the astrocytic marker glial fibrillary
acidic protein (GFAP; Figure 2H), or the progenitor cell
marker nestin (Figure 2I). The predominant phenotype ofell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 299
Table 1. Stereological Quantification of Donor Cells in nmd
Spinal Cord after Transplantation
No of animal analyzed 24
Total cell counts 8,795 ± 526
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iPSC-Derived Neural Stem Cells for SMARD1transplanted cells was neuronal, as demonstrated by dou-
ble-positive staining for the neuronal-specific antigen
MAP2 and GFP (41.9% ± 5.2%) (Figures 2C and 2E). Immu-
nohistochemical detection of the combined presence of
glial antigens (glial fibrillary acidic protein and O4) and
GFP demonstrated that astrocytes comprised 25.6% ±
3.1% of the cells, whereas 4.4% ± 2.4% were oligodendro-
cytes (Figure 2C). In addition, 21.6% ± 5.1% of GFP donor
cells maintained the features of NSC/progenitor cells and
expressed both nestin and GFP (Figure 2C).
We also evaluated whether engrafted NSCs can acquire a
motor neuronal phenotype. A fraction of the transplanted
cells presented motor neuronal features, as suggested by
their morphology and reactivity for motor-neuron-specific
markers, including CHAT (Figure 2G). Unbiased stereologi-
cal quantification demonstrated that the number of
CHAT-GFP cells was 4.1% ± 0.3% cells per spinal cord. No
adverse effects were observed after iPSC-derived NSC
transplantation.
Transplantation of iPSC-Derived NSCs Improves the
Neuromuscular Phenotype and Increases Survival of
SMARD1 Mice
We evaluated whether transplantation of WT iPSC-derived
NSCs could ameliorate the phenotype and extend survival
in nmdmice. Functional recovery was assessed in all animal
groups by blind assessment of their overall appearance,
weight, neuromuscular function (rotarod test), and sur-
vival after transplantation (Figure 3). The first clinical
symptoms in nmd mice presented in the second postnatal
week. The mice then rapidly developed muscle weakness
starting in the hind limbs, which were dorsally contracted,
causing impaired locomotor activity. The limited limb
extension made standing on all four limbs impossible. Ho-
mozygotes clenched their hind limbs when picked up by
the tail and could not grasp a cage cover when held against
it. As the disease progressed, the weakness was generalized
to involve the forelimbs. At 3 weeks, in transplanted nmd
mice, the hind limb muscles were ameliorated in compari-
son to their nmd littermates, who presentedmusclewasting
and marked contracture of the hind limbs (Figure 3A).
Mutant mice were severely paralyzed by the age of 5 weeks.
At the age of 5 weeks, all nmd mice failed the rotarod test
and could not remain on the accelerating wheel for longer
than a few seconds (p < 0.0001 versus control siblings)
(Figure 3B).300 Stem Cell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The AutBy contrast, transplanted nmdmice at 3 weeks of age did
not present a typical hind limb posture and could still
perform the rotarod test at 5 weeks of age (p < 0.0001 versus
untreated), although they exhibited a decrease in perfor-
mance when compared with their wild-type (WT) siblings.
At each time point, the performance of the transplanted
nmd mice was significantly superior to the untreated ani-
mals (p < 0.0001 versus untreated nmdmice, until 8 weeks)
(Figure 3B). The growth rates of the transplanted and un-
transplanted nmdmice, as measured bymean body weight,
were almost indistinguishable from that of their control lit-
termates from birth up to 1 week of age; however, starting
from 2 weeks of age, the nmd mice presented a reduced
mean body weight compared with their control siblings.
By contrast, transplanted nmd mice displayed an interme-
diate growth rate significantly different from that of un-
treated nmd mice and controls at 8 weeks (transplanted:
16.9 ± 1.9 g versus vehicle-treated: 12.8 ± 1.4 versus fibro-
blast-treated 11.9 ± 1.7; p < 0.0001, n = 24 per group) (Fig-
ure 3C). The transplanted nmd mice also had significantly
increased mean lifespans compared to sib-matched vehicle
and fibroblasts-treated nmd mice; thus, the effect was spe-
cific (treated 92.3 ± 27.8 versus vehicle 69.6 ± 27.3; p =
0.006; n = 24; c2 = 7.3; versus fibroblasts treated: 67.2 ±
28.2 p = 0.004; n = 24; c2 = 8.2) (Figure 3D).
Donor Cells Provide Neuroprotection to Endogenous
Motor Neurons and Their Muscle Connections
To analyze the factors underlying the improved motor
behavior and survival in transplanted nmdmice, we inves-
tigated spinal cord motor neurons and ventral spinal nerve
roots from a quantitative perspective (Figure 4). Relative to
WT littermates, a severe loss of spinal motor neurons was
detected in vehicle-treated nmdmice. By contrast, in trans-
planted nmd mice, we detected a significant protection of
motor neurons in the lumbar spinal cord, with a 65% pres-
ervation of motor neurons at 6 weeks with respect to 44%
in untreated mice (transplanted versus nontransplanted
mice p < 0.0001) (Figure 4A). At the end stage of the disease,
the number of motor neurons in untreated animals was
reduced to 25% of that observed in WT, whereas trans-
planted nmd animals retained 42% (treated versus un-
treated nmd, p < 0.0001) (Figure 4B). Prominent neuronal
loss was observed in 6-week-old nmd mice, as evidenced
by a significant reduction in the diameter of the L4–L5
ventral nerve roots. Similar reductions were detected in
all lumbar ventral roots analyzed. By contrast, only a
limited reduction was detected in the diameter of ventral
roots of age-matched transplanted mice (Figures 4C and
4D). The transplanted animals also presented a partial pres-
ervation of large axon density (Figures 4E and 4F). These
data suggest that neuroprotection is a key factor in the
beneficial effect of NSC transplantation in nmd mice.hors
Figure 3. NSC Transplantation Improves
Neuromuscular Function and Survival in
nmd Mice
(A) Representative pictures of transplanted
nmd mice (nmd-trans) showing their
greater capacity to open and extend their
lower limbs in comparison to vehicle-
treated (nmd-veh) and fibroblasts-treated
(nmd-fibro) animals, with features similar
to wild-type (WT).
(B) The time that transplanted mice could
remain on the rotarod treadmill was
increased relative to nmd-veh mice and
nmd-fibro at 8 weeks of age (n = 24 per
group; *p < 0.0001). Error bars show
the SDs.
(C) The mean body weight of nmd-trans
mice was increased relative to nmd-veh
mice and nmd-fibro (at 8 weeks; n = 24 per
group; *p < 0.0001).
(D) Kaplan-Meier survival curves of nmd-
trans and nmd-veh mice; nmd-trans mice
(n = 24 per group) survived significantly
longer than nmd-veh (p = 0.006) and nmd-
fibro mice (p = 0.004).
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Factors and Positively Influence SMARD1 Murine
Motor Neurons
The improvement in nmdmice after transplantation led to
our investigation of possible mechanisms, in which we
assessed whether or not WT iPSC-derived NSCs produce
neuroprotective factors that affect SMARD1 murine motor
neurons (Figures 5A–5D). The results indicated that NSCs
do indeed produce such factors, including glial cell-derived
neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF), transforming growth factor-a (TGF-a), and
neurotrophin-3 (NT3) (Figures 5A–5D).
To identify donor NSC effects on SMARD1 pathogenesis,
we used a coculture system containing a bottom layer of
primary motor neurons from nmd mice and a top layer of
human WT NSCs seeded onto a microporous membrane,
which permits the diffusion of soluble factors only into
the lower compartment (Figure 5E). Typical images of the
axon/growth cone are shown in Figures 5F and 5G. Alone,
SMARD1mouse primary motor neurons had much shorter
axons compared to wild-type motor neurons (p < 0.00001)
(Figure 5H). However, coculture of the SMARD1motor neu-
rons in the presence of human NSCs resulted in an
increased axon length (Figure 5H). Furthermore, the nmd
mice had significantly smaller motor neuron growth cones
compared to wild-type (p < 0.00001), and their growth
cone size increased following NSC coculture (p <
0.00001) (Figure 5I). These results suggested that neurotro-
phin expression could enhance axon length, which weStem Ctested by neutralizing individual cytokines or combina-
tions of cytokines with antibodies added to the culture
media. The result was a significantly reduced axon length
for nmd mouse motor neurons following neutralization of
GDNF, BDNF, and NT3 (p < 0.01) (Figure 5J).
Then, we investigated the effects of NSCs on nmd
neuronal survival. Nmd motor neurons in standard motor
neuronal medium do not present a reduction in cell
survival; however, in a neurotoxic environment, which
was provided by lipopolysaccharide-activated microglial-
conditioned media, they present a reduction in cell sur-
vival respect to wild-type cells (Figures 5K and 5L). In this
experimental setting, we demonstrated that exposure to
NSCs significantly promoted nmd mouse motor neuron
survival (p < 0.001 versus untreated cells) in an inflamma-
tory/toxic environment.
WT NSCs Protect Vulnerable iPSC Spinal Motor
Neurons Derived from SMARD1 Patients
Our next question was whether or not WT iPSC-derived
NSCs protect human SMARD1 iPSC-derived motor neu-
rons against degeneration induced by loss of IGHMBP2.
For this purpose, we reprogrammed fibroblasts of SMARD1
patients and healthy individuals into iPSCs (Table 2) and
differentiated them in motor neurons. The direct moni-
toring of the phenotype was obtained with a transduction
of a lenti-Hb9::eGFP construct (Marchetto et al., 2008). In
addition, we evaluated the effect of WT NSCs on SMARD1
motor neurons (Figure 6A). The human motor neuronsell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 301
Figure 4. NSC Transplantation Increases
Motor Neuron and Axon Number
(A and B) Motor neuronal count in the
lumbar spinal cord of transplanted (nmd-
trans), vehicle-treated (nmd-veh), and
wild-type (WT) mice (data represent the
mean ± SD) at 6 weeks of age (A) and at the
end stage of the disease (B) (n = 6 per group
per time point).
(C and D) Quantification of axons in the L4
anterior roots in WT, nmd-veh, and nmd-
trans (the data represent the mean ± SD) at
6 weeks of age (C) and at the end stage of
the disease (D) (n = 6 per group per time
point). These data demonstrate a signifi-
cant increase in motor neuron and axon
counts after transplantation compared to
nmd-veh mice (*p < 0.0001).
(E and F) Representative cross-section pic-
tures of L4 ventral roots of spinal cord
lumbar segment from WT mice, nmd-trans
mice, and nmd-veh mice at 6 weeks of age
(E) and at the end stage of the disease (F).
Scale bar, 50 mm.
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(Figure 6B). For further evaluation, we examined some
motor neuron features that are likely relevant to SMARD1
pathogenesis, including cell survival, axonal elongation,
and growth cone formation. Although at 5 weeks we
observed no significant reduction in cell number and
axonal length (Figures 6C–6E), at 8 weeks SMARD1 iPSC-
derived motor neurons had a significantly reduced cell
number and axon length compared to those from WT
iPSCs (p < 0.001), indicating an apparent cell autonomous
degeneration in vitro of SMARD1 motor neurons in long-
term culture, rather than a developmental defect (Figures
6F–6H).
Addition of humanNSCs (hNSCs), however, in coculture
with SMARD1 motor neurons protected the neurons,302 Stem Cell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Autwhich had improved survival at 8 weeks of culture
(p < 0.001, ANOVA) (Figure 6F). The SMARD1 motor
neurons that were cocultured with NSC also had increased
neurite lengths compared to untreated neurons (p < 0.001,
Kolmogorov-Smirnov test) (Figure 6G). Thus, NSCs can
protect human motor neurons from SMARD1-induced
degeneration.
We hypothesized that upregulation of neurotrophin
expression might be involved in this amelioration, as was
the case in murine motor neurons, so we again neutralized
the relevant cytokines by adding neutralizing antibodies
to the media. Neutralizing GDNF and BDNF, which we
selected based on the murine findings, resulted in signifi-
cantly decreased axon length for SMARD1 motor neurons
(p < 0.01) (Figure 6H).hors
Figure 5. NSCs Produce Neurotrophins and
Protect Motor Neurons of nmd Mice
(A–D) The amounts of (A) GDNF, (B) BDNF, (C)
TGF-a, and (D) NT3 secreted by NSCs were deter-
mined by ELISA, which revealed a significant
production of these neuroprotective substances
in comparison to fibroblasts *p < 0.00001, two-
tailed Student’s t test. Mean ± SD, n = 12 inde-
pendent experiments for each cytokine.
(E) Schematic diagram of the coculture of human
NSCs and nmd motor neurons.
(F) Representative images of neurite outgrowth.
Cells were stained with phospho-tau protein (red
signal). Nuclei were counterstained with DAPI
(blue signal).
(G) High-power magnification of NF-stained (red)
axonal growth cones in cultured motor neurons.
(H and I) Average length of axons (H) and growth
cone area of motor neurons (I) from nmd mice, in
coculture with human NSCs. Motor neurons
from SMA mice cocultured with human NSCs
(treated, tr) exhibited an increase in axon length
and size of growth cone with respect to nmd
mouse motor neurons not cocultured with human
NSCs (vehicle, veh) (*p < 0.00001, two-tailed
Student’s t test; mean ± SD, n = 4 independent
experiments for each condition).
(J) The average axonal length of cocultured nmd
mouse motor neurons was reduced after cytokine
neutralization of cytokine production by human
NSCs in the case of GDNF, BDNF, and NT3 (*p <
0.01, two-tailed Student’s t test; mean ± SD, n = 4
independent experiments for each condition).
(K and L) Quantification of the number of SMI32-
positive nmd murine motor neurons in the pres-
ence of human NSC and microglial-conditioned
media with (K) and without (L) LPS. The number
of nmd mouse motor neurons in cultures with
microglia+ LPS was reduced but was increased in
coculture with human NSC (*p < 0.001, ANOVA,
mean ± SD, n = 4 independent experiments for
each condition). Scale bars, (F) 75 mm; (G) 5 mm.
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Table 2. Characteristics of Human Fibroblast-Derived Induced Pluripotent Stem Cell SMARD1 Lines and Their Controls
iPSC Line Diagnosis Mutations IGHMBP2 Sex Age Reprogramming Strategy Reference
SMARD 1.1 SMARD I c.2125C > Tp.709Q > X Female 3 nonviral 6 factors: OSKM+LN this report
SMARD 1.2 SMARD I c.2125C > Tp.709Q > X Female 3 nonviral 6 factors: OSKM+LN this report
SMARD 1.3 SMARD I c.2125C > Tp.709Q > X Female 3 nonviral 6 factors: OSKM+LN this report
SMARD 2.1 SMARD I c.121 delC/c.439C > T
p.Gln41ArgfsX48/p.Arg147X
Female 2 nonviral 6 factors: OSKM+LN this report
SMARD 2.2 SMARD I c.121 delC/c.439C > T
p.Gln41ArgfsX48/p.Arg147X
Female 2 nonviral 6 factors: OSKM+LN this report
SMARD 2.3 SMARD I c.121 delC/c.439C > T
p.Gln41ArgfsX48/p.Arg147X
Female 2 nonviral 6 factors: OSKM+LN this report
19.9 healthy donor — Male newborn nonviral 6 factors: OSKM+LN Yu et al., 2009
CTR AC 1.1 healthy donor — Female 24 nonviral 6 factors: OSKM+LN this report
CTR AC 1.2 healthy donor — Female 24 nonviral 6 factors: OSKM+LN this report
CTR AC 13 healthy donor — Female 24 nonviral 6 factors: OSKM+LN this report
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Motor Neurons
Because it has been described that the GSK-3 and HGK
kinases pathways can regulate motor neuronal survival of
ALS and wild-type motor neurons (Yang et al., 2013), we
sought to examine if NSCs could protect human SMARD1
motor neurons from death caused by inactivation of
PI3K/AKT and HGK kinases.
Growth factors such as GDNF are reported to be activa-
tors of the AKT/PI3K pathway that in turn inhibits GSK3b
activity (Zuo et al., 2013). Furthermore, PI3K/Akt activity
is decreased inmotor neurons of both sporadic and familial
ALS patients, as well as inmutant SOD1mice, whereas acti-
vation of PI3K/Akt or inhibition of GSK3b can increase ALS
motor neuron survival (Yang et al., 2013). To identify mo-
lecular targets that might be acted on by NSCs to protect
SMARD1motor neurons, we carried out studies employing
a Phospho-Kinase Antibody Assay to examine the site-spe-
cific phosphorylation of GSK3b in the presence or absence
of NSCs in motor neuron cocultures. In NSC-treated
SMARD1 motor neurons, levels of GSK-3PSe9 phosphory-
lation were strongly elevated in a dose-dependent manner
in coculture conditions, as demonstrated by immunocyto-
chemistry andwestern blot (p < 0.01) (Figures 7A–7C), indi-
cating that GSK-3P was inhibited.
NSCs can act on a biologically and pharmacologically
meaningful target, GSK-3, so we tested further commer-
cially available GSK-3 inhibitors in our survival assay. Of
these, GSK-3 inhibitors VIII and XIII (Yang et al., 2013) pro-
duced a consistent survival improvement but one that was
reduced compared to the effect of NSCs (Figure 7D). As an
additional step, we compared NSCs and these two GSK-3304 Stem Cell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Autinhibitors (10 mM) for their ability to protect motor neu-
rons from death resulting from PI3K/AKT inactivation.
Coincubation of NSCs with the PI3K inhibitor LY294002
(10 mM) attenuated the motor neuron death that
LY294002 alone induced (Figure 7D). We found that the
VIII and XIII inhibitors conferred some protection on
SMARD1 motor neurons but produced only a small
increase in motor neuron survival respect to NSCs. Similar
results were obtained using the more potent and selective
PI3K inhibitor PI-103 (1 mM) (Figure 7D). Overall, these
findings indicated that inhibiting GSK-3 might assist in
promoting survival, but the possibility remained that the
comparatively superior effect of NSCs might arise from
additional molecular events.
Thus, we assessed the HG kinase pathway and showed
that NSC blocks the JNK/c-JUN-mediated cell death
signaling cascade in SMARD1 motor neurons that are
under the control of HG kinase. HG is a kinase involved
in the phospho-c-JUN-mediated neuronal cell death
pathway, and inhibition of this kinase prevents activation
of apoptosis. JNK is part of a central stress signaling
pathway implicated in neuronal plasticity, regeneration,
and cell death of neuronal and nonneuronal cells (Herde-
gen et al., 1997).
As shown in Figure S4, exposure of SMARD1 motor
neurons to NSCs blocks phosphorylation and therefore
activation of c-JUN, JNK, MKK4, and TAK1 (Figure S4).
Therefore, in the coculture system, NSCs may exert neuro-
protective effects by blocking activation of the proapopto-
tic JNK, MKK4, and TAK1 signaling cascade.
Our results support the hypothesis that NSC treatment
inhibits activation of GSK-3 and HGK kinases in our motorhors
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iPSC-Derived Neural Stem Cells for SMARD1neuron cultures and are consistent with the idea that this
inhibition may be a significant therapeutic target for
SMARD1.DISCUSSION
Increasingpreclinical evidence suggests thatNSC transplan-
tationcanexert a therapeutic effectonmotorneurondisease
phenotypes (Donnelly et al., 2012). This positive effect is
likely related to multiple mechanisms including not only
replacement of different CNS cell populations but also
neuroprotection of host motor neurons by different factors
produced by donor cells (Boulis et al., 2011). Previously, we
reported that primary murine NSC transplantation can
improve the disease phenotype in a SMARD1mouse model
(Corti et al., 2006). These data demonstrated the therapeutic
potential of NSC transplantation for this disease.
In the present study, we demonstrated that transplanted
human iPSC-derived NSCs can engraft into the SMARD1
spinal cord, also in the anterior horns, the areas of active
degeneration, after which they differentiate into the three
major neuroectodermal lineages and generate motor-
neuron-like cells, even if in a small proportion. Transplan-
tation of iPSC-derived NSCs significantly improved the
neurological phenotype and survival of nmdmice. Indeed,
this transplantation significantly correlated with a reduced
pathology of the spinal cord and protection of endogenous
motor neurons. These results build upon the findings from
our previous work in regards to translational possibilities:
pluripotent cell sources, particularly iPSCs, are much
more readily available and accessible than CNS primary-
derived NSCs.
With these results, we provide evidence that the trans-
plantation of iPSC-derived NSCs could have a beneficial
role in modifying the course of SMARD1. Regarding the
translational safety of iPSC-derived cells, onemajor finding
of this study is that adverse events such as tumorigenesis or
abnormal growth were not observed, even if our observa-
tional time is limited. Although NSC transplantation was
not sufficient to fully rescue the nmdphenotype, the behav-
ioral improvements and enhanced survival were signifi-
cant. Theneurological phenotypic improvement correlated
with a significant modification in spinal cord pathology,
and the motor neuron count in NSC-transplanted relative
to vehicle-treated and fibroblasts-treated mice confirmed a
significant reduction in neural cell degeneration.
Weobserved the generationof a lowproportion of donor-
derived motor neurons, as evaluated by immunopatholog-
ical characterization, which were correctly located in the
anterior horns. In addition, we detected an increased num-
ber of endogenous motor neurons as well as myelinated
axons in iPSC-transplanted nmd mice compared withStem Cvehicle-treated controls. Overall, the functional improve-
ment in the SMARD1 mouse models was supported by
the results of our neuromuscular function tests and by the
improved survival of transplanted mice. NSC transplanta-
tion increased survival by 30% compared with the
vehicle-treated group. The extended survival time resulting
from stemcell transplantation, although limited, is a signif-
icant finding. Similarly, theneuromuscular function test re-
sults in this study must be considered in the context of
decreased disease severity; treated animals could perform
the rotarod task, even if with lower performance respect
to the wild-type, whereas untreated animals would never
be able to execute the task. Therefore, although the amelio-
ration was not complete, it was relatively substantial.
In addition, human iPSC-derived NSCs produce neuro-
trophic factors that may be neuroprotective of murine
and human motor neurons by paracrine signaling, as our
coculture results suggest. This neurotrophic benefit of
NSCs indicates that they can lessen some of the effects of
SMARD1 pathogenesis. Particularly promising is the
finding that NSCs exert this protection in motor neurons
derived from reprogrammed SMARD1 fibroblasts. We also
showed that iPSCs from SMARD1 patients are a suitable
model for evaluating cellular features of motor neuron dis-
ease degeneration. Overall, NSC coculture improvedmotor
neuron survival, increased neurite length, and boosted
growth cone size of SMARD1 iPSC-derived motor neurons.
Our mechanistic studies of NSC protective effects of
human SMARD1 motor neurons showed that NSC cocul-
ture increased GSK3b phosphorylation, which would be
expected to elicit decreased kinase activity, a feature associ-
ated with motor neuron survival (Yang et al., 2013). In
keeping with this finding, our results also demonstrated
that NSC coculture inhibits the JNK/c-JUN-mediated cell
death signaling cascade in motor neurons that HGK kinase
controls. Overall, these findings indicate that NSC treat-
ment inhibits GSK-3 and HGK kinase activation in our mo-
tor neuron cultures and suggest an important therapeutic
target for SMARD1.
In conclusion, this report provides evidence that NSCs
derived from pluripotent cells are a potentially useful
therapeutic tool to ameliorate SMARD1 disease phenotype.
Combining cell transplantation treatment with drug or
gene therapy might further increase the therapeutic effi-
cacy to a clinically significant level for SMARD1 and other
motor neuron diseases.EXPERIMENTAL PROCEDURES
Generation of iPSCs
Reprogramming of human skin fibroblasts was executed as
previously described (Corti et al., 2012) with oriP/EBNA1-based
episomal vectors encoding the human genes OCT4, SOX2,ell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 305
Figure 6. NSCs Protect Human Spinal Motor Neurons in Culture from SMARD1 Degeneration
(A) Schematic diagram of experimental design: motor neuron differentiation and coculture of SMARD1 cells with wild-type human NSCs.
(B) Representative images of SMARD1 motor neurons in culture: compared to wild-type (left panel), the number of SMARD1 motor neurons
is significantly decreased in long-term culture without NSCs (middle panel) (n = 5 independent experiments for each condition). The
coculture with NSCs increased the number of SMARD1 motor neuron (right panel). Motor neurons were stained with Hb9::GFP (green) and
CHAT (red) and nuclei were counterstained with DAPI (blue signal). Merged images are presented. Scale bar, 75 mm.
(legend continued on next page)
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iPSC-Derived Neural Stem Cells for SMARD1NANOG, LIN28, c-MYC, and KLF4. After nucleofection, fibroblasts
were seeded onto 33 10 cm dishes covered with Matrigel (BD Bio-
sciences) in fibroblast culture medium, which was changed every
other day. At 4 days after transfection, we substituted the fibroblast
culturemediumwith human embryonic stem cell culturemedium
(mTeSR, STEMCELL Technologies) for 8–10 days. At day 18 after
transfection, it was possible to recognize colonies with an iPSC-
like morphology. We then isolated the iPSC colonies that were
morphologically more similar to embryonic stem cells for further
analysis and expansion, as previously described (Corti et al., 2012).Differentiation of iPSCs into NSCs
We differentiated iPSCs into neuroepithelial cells using a pre-
viously described differentiation protocol (Corti et al., 2012).
iPSCs were seeded in neuronal medium based on Dulbecco’s
modified Eagle’s medium/F12 (Gibco, Invitrogen), supplemented
with MEM nonessential amino acids solution, N2, and heparin
(2 mg/ml; Sigma-Aldrich), thus promoting neuroepithelial
differentiation.
For cell expansion and clonal culture, NSCs were plated in
growth medium (NEP medium) containing FGF with or without
epidermal growth factor, as previously reported (Corti et al., 2008).Immunocytochemistry of iPSCs and Their Derivatives
Cells were fixed in 4% paraformaldehyde for 10 min, permeabi-
lized with 0.5% Tween 20 in PBS, and exposed to 0.1% Tween 20
with 10% horse serum. We incubated the cells with primary anti-
bodies overnight and with secondary antibodies for 1 hr (Alexa
Fluor, Invitrogen).We employed the following primary antibodies:
SSEA-3 (1:100, Chemicon), SSEA-4 (1:500, Chemicon), TRA1-60
(1:500, Chemicon), TRA1-81 (1:500, Chemicon), nestin (1:200,
Millipore), SOX1 (1:1000, R&D Systems), SOX2 (1:1000, Milli-
pore), TUJ1 (1:200, Millipore), GFAP (1:300, Sigma), Islet1/2
(1:200, Millipore), HB9 (1:200Millipore), CHAT (1:200, Millipore),
MAP2 (mouse monoclonal, 1:100; Sigma), O4 (10–20 mg/ml, Milli-
pore), and Musashi (1:200, Novus Biologicals). The Hb9::GFP gene
reporter was used to identify motor neuron cells, as described pre-
viously (Marchetto et al., 2008). For all imaging, we used a confocal
LEICA LCS2 microscope.Animal Models
The nmd mouse (B6.BKS Ighmbp2nmd-2J/J) possesses a homozy-
gous mutation in the Ighmbp2 gene. Heterozygous mice were(C–E) At 5 weeks, no difference was detected in number of SMARD1
lengths in basal conditions (D) and after exposure to antibodies neutra
each condition).
(F) Treatment of the cultures with NSCs was protective of motor neuron
cells (8 weeks, *p < 0.001, ANOVA, n = 5 independent experiments fo
(G) At 8 weeks, untreated SMARD1 motor neurons had shorter axons th
longer axons than untreated SMARD1 motor neurons (p < 0.001, Ko
condition).
(H) Relevant cytokines were neutralized by antibody addition to the m
reduced axon length of SMARD1 motor neurons respect to control imm
murine data (p < 0.01, n = 5 independent experiments for each con
SMARD1 patients and WT subjects (three clones for each subject).
Stem Cbred to generatemice homozygous for themutation. Homozygous
nmdmutantmice andWT littermateswere employed for the exper-
iments and analyses. The genotypes of the mice were confirmed
using a PCR-based assay with genomic DNA from tail biopsies as
described previously (Cox et al., 1998). All transgenic animals
were purchased from Jackson Laboratory. All animal experiments
were approved by the University of Milan and Italian Ministry of
Health review boards, in compliance with US National Institutes
of Health Guidelines (Corti et al., 2006).
Neural Stem Cell Transplantation
Before cell transplantation, the donor cells were genetically engi-
neered to express GFP under a cytomegalovirus promoter (Corti
et al., 2012). The cells were harvested and prepared for transplan-
tation as described previously (Corti et al., 2012). The graft recip-
ients were 1-day-old nmdmice. As previously described, cells were
transplanted into the spinal cords of animals after cryoanesthesia
(Corti et al., 2009, 2010, 2012). An injection micropipette
(100 mm tip diameter) was inserted into the anterior horns. A
slow infusion of 2 ml of cell suspension (10,000 cells/ml 3 two
horns) was injected into the C4–C5 and L1–L2 regions of the re-
cipients’ spinal cords. After injection, the needle was slowly
removed. All of the transplanted mice survived after the injection
without any observed side effects. As controls, nmd mice received
vehicle or human fibroblasts only using the same surgical proce-
dure (Corti et al., 2009, 2010, 2012). The experimental group
included 24 mice (12 males), as did the vehicle control group
(24 mice; 12 males). The animals were evaluated by a blinded
examiner for weight, rotarod performance, survival record, and
histological evaluation of donor cell phenotype until the end
stage. The immunosuppressor FK506 was administered intraperi-
toneally at 1.0 mg/kg to all animals in all groups for the entire
length of the experiment.
The study was designed so that littermates were distributed
equally among the transplanted and untransplanted groups. Sepa-
rate groups of animals (each composed of six mice per time point
per condition) were sacrificed for histological analysis, quantifica-
tion of motor neurons and axons, and muscle analysis.
Neuromuscular Evaluation and Survival
All groups of nmdmice were monitored daily after transplantation
or vehicle injection for phenotypic hallmarks of disease. The
investigators that executed the functional assessment were blind
to the treatment. Body weight was recorded, and motor functionmotor neurons with respect to wild-type as well as in their axonal
lizing neurotrophins (E). ANOVA (n = 5 independent experiments for
s in long-term culture, increasing their survival respect to untreated
r each condition).
an wild-type cells. SMARD1 motor neurons cocultured with NSCs had
lmogorov-Smirnov test, n = 5 independent experiments for each
otor neuron culture media; neutralizing GDNF and BDNF significantly
unoglobulin G (IgG). These growth factors were selected based on
dition). These experiments were performed with iPSC lines of two
ell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 307
(legend on next page)
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iPSC-Derived Neural Stem Cells for SMARD1was tested weekly with an accelerating rotarod device (4–40 rpm;
Rota-Rod 7650; Ugo Basile). We recorded the length of time that
each mouse remained on the rotarod. Mortality was scored as the
age at death. The animals were sacrificed when the mouse was un-
able to right itself within 30 s when positioned in a supine position
(Li et al., 2000).
Tissue Analysis
The animals were sacrificed at the end stage of the disease,
perfused, and fixed with 4% paraformaldehyde in PBS (pH 7.4).
The spinal cord was isolated, immersed in paraformaldehyde
solution for 1 hr followed by 20% sucrose solution in PBS
(pH 7.4) overnight, and frozen in Tissue-Tek Optimal Cutting
Temperature compound with liquid nitrogen. The tissues were
cryosectioned and mounted on gelatinized glass slides. Every
tenth section of 20 mm was collected. All sections were blocked
with 1% fetal calf serum in PBS and permeabilized with 0.25%
Triton X-100. Sections were processed for multiple markers to
determine the cellular phenotype of GFP-labeled cells. Primary
antibodies were added overnight at 4C for NEUN (mouse
monoclonal, 1:200; Chemicon International), beta III-tubulin
(mouse monoclonal, 1:200; Chemicon International), MAP2
(mouse monoclonal, 1:200; Sigma-Aldrich), anti-CHAT (rabbit
polyclonal; 1:100 Chemicon International), nestin (1:200, Milli-
pore), oligodendrocyte marker O4 (mouse monoclonal, 1:200;
Chemicon), and glial fibrillary acidic protein (GFAP, mouse
monoclonal, 1:200; Sigma). Mouse and rabbit antibodies conju-
gated with R-phycoerythrin, Cyanine-3, or biotin (1:200; Jackson
ImmunoResearch Laboratories and Dako) were used for 1 hr at
room temperature as secondary antibodies when unconjugated
primary antibodies were used. The numerical cell density on
fixed sections was estimated using the optical dissector method
as described previously (Locatelli et al., 2007; Corti et al., 2008).
Optical dissectors sized at 100 3 70 3 14 mm were randomly
sampled, and the number of positive cells in each dissector was
quantified. The density was calculated by dividing the total num-
ber of donor cells by the total volume of optical dissectors. The
total volume of tissue per specimen (Vcord) containing donor
cells was calculated using the Cavalieri method (Corti et al.,
2008). This total volume of tissue, multiplied by the number ofFigure 7. Mechanistic Studies of NSC Coculture Effects on SMARD
(A) NSC coculture promotes the phosphorylation of GSK-3 on the S9 res
(n = 5 independent experiments for each condition; *p < 0.01).
(B) Western blot analysis of the phosphorylation of GSK-3 on S9 s
untreated samples.
(C) Representative image of immunocytochemistry to detect phosp
(TR-SMARD1) or absence (SMARD1) of NSCs. Motor neurons were stai
stain. Scale bar, 75 mm.
(D) A survival assay using GSK-3 inhibitors VIII and XIII (without coc
not as efficacious as that achieved with NSC coculture (upper panel)
induced dose-dependent death of motor neurons (middle panel), and
motor neuron death. NSCs were superior to the two GSK-3 inhibitors i
obtained similar results with PI-103, a stronger and more specific PI3
condition; *p < 0.01).
(E) A schematic representation of the GSK-3 survival pathway that is m
iPSC lines of two SMARD1 patients and WT subjects (three clones for
Stem Cdonor cells per mm3 (Nv), gave the total number of donor cells
per specimen (n = Nv 3 Vcord).
Histological Analysis
The lumbar spinal cord region was processed for paraffin embed-
ding. Serial cross sections (12 mm thick) of the lumbar spinal cords
weremade, and every fifth sectionwas processed andNissl stained,
as reported previously (Grondard et al., 2005). The number and
diameter (soma) of all motor neurons counted in these cross sec-
tions (n = 50 for each mouse) were analyzed. The sections were
analyzed at 200 3 magnification in the anterior horn (either left
or right) for the presence of all neurons in that region. All cells
were counted within the ventral horn below an arbitrary horizon-
tal line drawn from the central canal. Only neuronal cells with at
least one nucleolus located within the nucleus were counted, as
previously described (Grondard et al., 2005).
The axonal count was performed as previously described on
semi-thin transverse sections (1 mm) stained with toluidine blue
(Corti et al., 2006). Lumbarra anterior roots were examined for
axon counting on the optic microscope.
Coculture of Murine Spinal Primary Motor Neurons
and Neural Stem Cells
We derived primary motor neuron cultures from E12.5 nmd and
WT mice as previously described (Corti et al., 2008). The culture
medium was a motor neuron medium supplemented with a cock-
tail of trophic factors (Corti et al., 2008). We performed a coculture
assay to separate the primary motor neurons from the NSCs with a
microporous membrane as previously described (Locatelli et al.,
2007; Corti et al., 2008). To evaluate whether hNSCs can protect
mouse spinal cord motor neurons of nmd mice from the neuro-
toxic effects of activated microglia, mouse microglia were derived
as previously described (Xiao et al., 2007) and cultured, and the
conditioned mediumwas collected after 24 hr from control micro-
glia and microglia activated with 100 ng/ml of lipopolysaccharide
(LPS) (Sigma). The microglial-conditioned medium was then
filtered and used for neuronal survival assays in the presence of
hNSCs. For neuron counts, ten fields were randomly chosen for
each sample. At least four independent experiments were consid-
ered for each condition.1 Motor Neurons
idue, thus inhibiting enzyme activity with respect to untreated cells
howing the increased phosphorylation in treated cells relative to
horylation of the S9 residue of the GSK3 enzyme in the presence
ned with Hb9-GFP (green) and p-GSK-S9 (red). Blue, DAPI nuclear
ulture of NSCs) resulted in a significant improvement in survival but
. In a further step, we inhibited PI3K/AKT using LY294002, which
then evaluated the ability of NSCs and GSK-3 inhibitors to attenuate
n protecting motor neurons from the effects of PI3K inhibition. We
K inhibitor (lower panel) (n = 5 independent experiments for each
odulated by NSC coculture. These experiments were performed with
each subject).
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with NSCs
To develop a coculture of NSCs and human motor neurons, we
plated iPSC-derived motor neurons on the bottom chamber of a
transwell coculture system and cultured them in the presence of
human NSCs (Corti et al., 2008, 2012). Only soluble components
could diffuse through the porous membrane that separated the
two compartments. In coculture experiments for the evaluation
of the effect of neurotrophic factors produced from NSCs, we
cultured motor neurons in the absence of further addition of
growth factors. To identify motor neurons, fixed cultures were
stained using antibodies against bIII-tubulin (1:200), ISLET1/2
(1:200), HB9 (1:200), CHAT (1:200; Millipore), mouse anti-micro-
tubule-associated protein 2 (MAP2, 1:100; Sigma), and SMI-32
(Covance, 1:500); in addition,we quantified themusing identifica-
tion ofHb9::GFP, counting ten randomly selected fields/well (three
wells/condition/experiment in four to five experiments). Morpho-
metric axonal lengthmeasurementwasmade using soma diameter
and length distance between two points. We analyzed differences
in the results (mean ± SEM for five independent experiments) with
the Kolmogorov-Smirnov test (http://www.physics.csbsju.edu/
stats/KS-test.n.plot_form.html).
Supplemental Experimental Procedures are available online.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2014.06.004.
AUTHOR CONTRIBUTIONS
C.S, M.N., and S.C. performed in vitro and in vivo experiments;
F.R. and M.R. performed stem cell in vitro experiments; G.R.
participated in neuropathological analysis and assisted with
data analysis; S.S. performed proteomic analysis; M.B. participated
in vivo experiments; N.B. contributed ideas and supported the
work; C.S. M.N., S.C., and G.P.C. conceived the experiments and
wrote the manuscript.
ACKNOWLEDGMENTS
We wish to thank the Associazione Amici del Centro Dino Ferrari
for their support. The financial support of research grants to
S.C. and G.P.C. is gratefully acknowledged: Telethon grant
GGP10062 (G.P.C.); Ministry of Health (S.C.): GR-2009-1483560
and GR-2010-2309463, FIRB RBFR08RV86.
Received: February 9, 2014
Revised: June 4, 2014
Accepted: June 5, 2014
Published: July 3, 2014REFERENCES
Boulis, N.M., Federici, T., Glass, J.D., Lunn, J.S., Sakowski, S.A., and
Feldman, E.L. (2011). Translational stem cell therapy for amyotro-
phic lateral sclerosis. Nat. Rev. Neurol. 8, 172–176.310 Stem Cell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The AutCorti, S., Locatelli, F., Papadimitriou, D., Donadoni, C., Del Bo, R.,
Crimi,M., Bordoni, A., Fortunato, F., Strazzer, S., Menozzi, G., et al.
(2006). Transplanted ALDHhiSSClo neural stem cells generate mo-
tor neurons and delay disease progression of nmdmice, an animal
model of SMARD1. Hum. Mol. Genet. 15, 167–187.
Corti, S., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S.,
Ronchi, D., Saladino, F., Bordoni, A., Fortunato, F., Del Bo, R.,
et al. (2008). Neural stem cell transplantation can ameliorate the
phenotype of a mouse model of spinal muscular atrophy. J. Clin.
Invest. 118, 3316–3330.
Corti, S., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Del
Bo, R., Papadimitriou, D., Locatelli, F., Mezzina, N., Gianni, F.,
et al. (2009). Motoneuron transplantation rescues the phenotype
of SMARD1 (spinal muscular atrophy with respiratory distress
type 1). J. Neurosci. 29, 11761–11771.
Corti, S., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Ron-
chi, D., Simone, C., Falcone, M., Papadimitriou, D., Locatelli, F.,
et al. (2010). Embryonic stem cell-derived neural stem cells
improve spinal muscular atrophy phenotype in mice. Brain 133,
465–481.
Corti, S., Nizzardo, M., Simone, C., Falcone, M., Nardini, M., Ron-
chi, D., Donadoni, C., Salani, S., Riboldi, G., Magri, F., et al. (2012).
Genetic correction of human induced pluripotent stem cells from
patients with spinal muscular atrophy. Sci. Transl. Med. 4, ra162.
Cox, G.A., Mahaffey, C.L., and Frankel,W.N. (1998). Identification
of the mouse neuromuscular degeneration gene and mapping of a
second site suppressor allele. Neuron 21, 1327–1337.
Donnelly, E.M., Lamanna, J., and Boulis, N.M. (2012). Stem cell
therapy for the spinal cord. Stem Cell Res. Ther. 3, 24.
Eckart, M., Guenther, U.P., Idkowiak, J., Varon, R., Grolle, B., Boffi,
P., Van Maldergem, L., Hu¨bner, C., Schuelke, M., and von Au, K.
(2012). The natural course of infantile spinal muscular atrophy
with respiratory distress type 1 (SMARD1). Pediatrics 129, e148–
e156.
Grohmann, K., Schuelke, M., Diers, A., Hoffmann, K., Lucke, B.,
Adams, C., Bertini, E., Leonhardt-Horti, H., Muntoni, F., Ouvrier,
R., et al. (2001). Mutations in the gene encoding immunoglobulin
mu-binding protein 2 cause spinal muscular atrophy with respira-
tory distress type 1. Nat. Genet. 29, 75–77.
Grondard, C., Biondi, O., Armand, A.S., Le´colle, S., Della Gaspera,
B., Pariset, C., Li, H., Gallien, C.L., Vidal, P.P., Chanoine, C., and
Charbonnier, F. (2005). Regular exercise prolongs survival in a
type 2 spinal muscular atrophy model mouse. J. Neurosci. 25,
7615–7622.
Guenther, U.P., Handoko, L., Laggerbauer, B., Jablonka, S., Chari,
A., Alzheimer, M., Ohmer, J., Plo¨ttner, O., Gehring, N., Sickmann,
A., et al. (2009). IGHMBP2 is a ribosome-associated helicase inac-
tive in the neuromuscular disorder distal SMA type 1 (DSMA1).
Hum. Mol. Genet. 18, 1288–1300.
Herdegen, T., Skene, P., and Ba¨hr, M. (1997). The c-Jun transcrip-
tion factor—bipotential mediator of neuronal death, survival and
regeneration. Trends Neurosci. 20, 227–231.
Hu, B.Y., and Zhang, S.C. (2009). Differentiation of spinal motor
neurons from pluripotent human stem cells. Nat. Protoc. 4,
1295–1304.hors
Stem Cell Reports
iPSC-Derived Neural Stem Cells for SMARD1Ito, D., Okano, H., and Suzuki, N. (2012). Accelerating progress in
induced pluripotent stem cell research for neurological diseases.
Ann. Neurol. 72, 167–174.
Jankowsky, A., Guenther, U.P., and Jankowsky, E. (2011). The RNA
helicase database. Nucleic Acids Res. 39, D338–D341.
Li, Y., Chopp, M., Chen, J., Wang, L., Gautam, S.C., Xu, Y.X., and
Zhang, Z. (2000). Intrastriatal transplantation of bone marrow
nonhematopoietic cells improves functional recovery after stroke
in adult mice. J. Cereb. Blood Flow Metab. 20, 1311–1319.
Locatelli, F., Corti, S., Papadimitriou, D., Fortunato, F., Del Bo, R.,
Donadoni, C., Nizzardo, M., Nardini, M., Salani, S., Ghezzi, S.,
et al. (2007). Fas small interfering RNA reduces motoneuron death
in amyotrophic lateral sclerosis mice. Ann. Neurol. 62, 81–92.
Marchetto, M.C., Muotri, A.R., Mu, Y., Smith, A.M., Cezar, G.G.,
and Gage, F.H. (2008). Non-cell-autonomous effect of human
SOD1G37R astrocytes onmotor neurons derived fromhuman em-
bryonic stem cells. Cell Stem Cell 3, 649–657.
Nizzardo, M., Simone, C., Rizzo, F., Ruggieri, M., Salani, S., Riboldi,
G., Faravelli, I., Zanetta, C., Bresolin, N., Comi, G.P., and Corti, S.
(2013). Minimally invasive transplantation of iPSC-derived
ALDHhiSSCloVLA4+ neural stem cells effectively improves theStem Cphenotype of an amyotrophic lateral sclerosis model. Hum. Mol.
Genet.
Teng, Y.D., Benn, S.C., Kalkanis, S.N., Shefner, J.M., Onario, R.C.,
Cheng, B., Lachyankar, M.B., Marconi, M., Li, J., Yu, D., et al.
(2012). Multimodal actions of neural stem cells in a mouse model
of ALS: a meta-analysis. Sci. Transl. Med. 4, ra164.
Xiao, Q., Zhao, W., Beers, D.R., Yen, A.A., Xie, W., Henkel, J.S., and
Appel, S.H. (2007).Mutant SOD1(G93A)microglia aremore neuro-
toxic relative to wild-type microglia. J. Neurochem. 102, 2008–
2019.
Yang, Y.M., Gupta, S.K., Kim, K.J., Powers, B.E., Cerqueira, A.,
Wainger, B.J., Ngo, H.D., Rosowski, K.A., Schein, P.A., Ackeifi,
C.A., et al. (2013). A small molecule screen in stem-cell-derived
motor neurons identifies a kinase inhibitor as a candidate thera-
peutic for ALS. Cell Stem Cell 12, 713–726.
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I., and
Thomson, J.A. (2009). Human induced pluripotent stem cells free
of vector and transgene sequences. Science 8, 797–801.
Zuo, T., Qin, J.Y., Chen, J., Shi, Z., Liu, M., Gao, X., and Gao, D.
(2013). Involvement of N-cadherin in the protective effect of glial
cell line-derived neurotrophic factor on dopaminergic neuron
damage. Int. J. Mol. Med. 31, 561–568.ell Reports j Vol. 3 j 297–311 j August 12, 2014 j ª2014 The Authors 311
